Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compositions and methods for managing weight
Unigen, Inc.
April 12, 2018 - N°20180099019

The present disclosure provides diels-alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such diels-alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, ...
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Acylated glucagon analogue
Boehringer Ingelheim International Gmbh
April 05, 2018 - N°20180094038

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glp-1 receptor as compared to human glucagon.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of human small leucine zipper protein in adipocyte differentiation procedure
Korea University Research And Business Foundation
April 05, 2018 - N°20180092962

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, slzip binds with pparγ2 to induce the formation of a complex of hdac3 and pparγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of pparγ2 and suppress the differentiation to ...
Compositions containing tannic acids and uses thereof
Syneurx International (taiwan) Corp.
April 05, 2018 - N°20180092935

Compositions (e. G., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are d-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.
Use of long-acting glp-1 peptides
Novo Nordisk A/s
March 29, 2018 - N°20180085435

The invention relates to use of long-acting glp-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Auspex Pharmaceuticals, Inc.
March 29, 2018 - N°20180085327

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar ...
Efficiently building nutrition intake history from images of receipts
Whatubuy Llc
March 22, 2018 - N°20180082139

This invention provides an efficient and feasible method, system and computer program for retrieving total nutrition facts from purchase transaction information including receipt images and other complementary data. The said facts are used to build up the nutrition intake history, provide nutrition intake reports and customized nutrition suggestions based on the users' personal health related information and nutrition intake data. ...
Sab as a biomarker for degenerative diseases and therapeutic sensitivity in cancers
The Florida International University Board Of Trustees
March 22, 2018 - N°20180080944

The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of src homology 3 domain binding protein 5 (sh3bp5 or sab) or the rna encoding sab protein in a biological sample obtained from the subject and identifying the subject as having the ...
Method for decreasing the body fat content in a subject by administering an actriib protein
Acceleron Pharma Inc.
March 22, 2018 - N°20180080012

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor ...
Remd Biotherapeutics, Inc.
March 22, 2018 - N°20180079820

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e. G., fully human antibodies, that specifically bind to and ...
Growth differentiation factor 15 (gdf-15) constructs
Amgen Inc.
March 22, 2018 - N°20180079790

Constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same
Zafgen, Inc.
March 22, 2018 - N°20180079737

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Fused heterocyclic compound
Takeda Pharmaceutical Company Limited
March 15, 2018 - N°20180072694

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (i) or a salt thereof, and use of the compound as a medicament ...
Inhibitors of histone deacetylase
March 15, 2018 - N°20180072671

Or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein x1, x2, x3, x4, x5, w1, w2, w3, and w4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective hdac3 inhibitors useful for protecting β-cells and ...
Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
University Of Innsbruck
March 15, 2018 - N°20180072654

Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurode-generative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e. G. Esters, ethers, amides), processes for their preparation and their application in the manufacture of ...
Injection composition comprising hyaluronidase for removal of topical fat
March 15, 2018 - N°20180071372

The present invention relates to an injection composition comprising hyaluronidase for topical fat reduction. More particularly, the present invention relates to an injection composition comprising 300 iu to 600 iu of hyaluronidase and a local anesthetic, an antihistamine, a lipolysis stimulator and a collagen production stimulator. The present invention promotes the reduction of topical fat tissue, thereby improving obesity and helping weight ...
Amylin analogues
Boehringer Ingelheim International Gmbh
March 15, 2018 - N°20180071366

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the ...
Carbazole-containing sulfonamides as cryptochrome modulators
Reset Therapeutics, Inc.
March 15, 2018 - N°20180071306

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula i wherein the variable r1, r2, r3, r4, r5, r6, r7, a, b, c′, d, e, f, g, h′, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula i to treat ...
Tesofensine, beta blocker combination formulation
Saniona A/s
March 15, 2018 - N°20180071250

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
Identification of bitter ligands that specifically activate human t2r receptors and related assays for ...
Senomyx, Inc.
March 08, 2018 - N°20180067114

The present invention relates to the discovery that specific human taste receptors in the t2r taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific ht2r9 alleles and their disparate activity in functional assays with the same biter ligands. The invention further relates to the use of these t2r receptors ...
Loading